Business
TG Therapeutics Announces Data Presentations at the Upcoming American Academy of Neurology 72nd Annual Meeting
NEW YORK, March 09, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that abstracts featuring ublituximab, the Company’s novel,
About this update from Tg Therapeutics, Inc.
[{"type":"text","content":"NEW YORK, March 09, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that abstracts featuring ublituximab, the Company’s novel, glycoengineered anti-CD20 monoclonal antibody, in relapsing forms of multiple sclerosis (RMS), have been selected for presentation at the upcoming American Academy of Neurology (AAN) annual meeting, to be held April 25 – May 1, 2020, in Toronto, Canada. Abstracts are now available online and can be accessed via the below links or on the AAN meeting website at www.aan.com.\n Oral Presentation Title: Long-term Follow-up Results from the Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 mAb, in Patients with RMS Presentation Date & Time: Sunday, April 26, 2020; 1:48 PM ETSession Name: S5: Multiple Sclerosis: Clinical Trials and Disease-modifying TherapyPresentation Number: 003Lead Author: Edward Fox, MD, PhD, Central Texas Neurology Consultants, Round Rock, TXAbstract Number: 1167 Poster Presentation Title: Baseline Demographics and Disease Characteristics from the ULTIMATE Phase III Trials Evaluating Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Patients with Relapsing Multiple Sclerosis Presentation Date & Time: Tuesday, April 28, 2020; 8:00 – 9:00 AM ETSession Title: Poster Session P8Presentation Number: 019Lead Author: Lawrence Steinman, MD, Stanford University, Stanford, CAAbstract Number: 4845 Following each presentation, the data presented will be available on the Publications page of the Company’s website at www.tgtherapeutics.com. ABOUT TG THERAPEUTICS, INC. TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing multiple therapies targeting hematological malignancies and autoimmune diseases. Ublituximab (TG-1101) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing umbralisib (TGR-1202), an oral, once-daily dual inhibitor of PI3K-delta and CK1-epsilon, which may lead to a differentiated safety profile. Both ublituximab and umbralisib, or the combination of which is referred to as \"U2\", are in Phase 3 clinical development for patien...